Placeholder

Diatrizoic Acid

  • # LGM Pharma is a Diatrizoic Acid CAS# 117-96-4 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Diatrizoic Acid
  • CAS #: 117-96-4
  • Mode of Action:

    Diatrizoate is an iodine-containing X-ray contrast agent. Iodated contrast agents were among the first contrast agents developed. Iodine is known to be particular electron-dense and to effectively scatter or stop X-rays. A good contrast agent requires a high density of electron-dense atoms. Therefore, the more iodine, the more "dense" the x-ray effect. Iodine based contrast media are water soluble and harmless to the body. These contrast agents are sold as clear colorless water solutions, the concentration is usually expressed as mg I/ml. Modern iodinated contrast agents can be used almost anywhere in the body. Most often they are used intravenously, but for various purposes they can also be used intraarterially, intrathecally (the spine) and intraabdominally - just about any body cavity or potential space.

  • Pharmacodynamics:

    Diatrizoate is the most commonly used water-soluble, iodinated, radiopaque x-ray contrast medium. Radiopaque agents are drugs used to help diagnose certain medical problems. They contain iodine, which blocks x-rays. Depending on how the radiopaque agent is given, it localizes or builds up in certain areas of the body. The resulting high level of iodine allows the x-rays to make a "picture" of the area. The areas of the body in which the radiopaque agent localizes will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.

  • Toxicity:

    High osmolal radiocontrast agents like diatrizoate are cytotoxic to renal cells. The toxic effects include apoptosis, cellular energy failure, disruption of calcium homeostasis, and disturbance of tubular cell polarity, and are thought to be linked to oxidative stress.

  • IUPAC: 3, 5-diacetamido-2, 4, 6-triiodobenzoic acid
  • ATC: V08AA01
  • DrugBank: DB00271
  • Formula: C11-H9-I3-N2-O4
  • Molecular Mass: 613.9021
  • Synonyms: 2,4,6-Triiodo-3,5-diacetamidobenzoic acid, 3,5-Bis(acetylamino)-2,4,6-triiodobenzoic acid, 3,5-Diacetamido-2,4,6-triiodobenzoic acid, 4-14-00-01308 (Beilstein Handbook Reference), Acide amidotrizoique, Acidum amidotrizoicum, Acidum diacetylaminotrijodbenzoicum, Amidotrizoate, Amidotrizoic acid, Amidotrzoique (acide), Benzoic acid, 3,5-bis(acetylamino)-2,4,6-triiodo-, Benzoic acid, 3,5-diacetamido-2,4,6-triiodo-, BRN 2225144, DIAT, DIAT [German], Diatrizoate, Diatrizoesaure, Diatrizoesaure [German], Diatrizoic acid, EC 204-223-6, EINECS 204-223-6, G 2-75, HSDB 4042, NSC 262168, Odiston, S 17, Triombrin, Triombrin [Russian], UNII-5UVC90J1LK, Urografin acid, Urogranoic acid, Urotrast
  • SMILES: CC(=O)Nc1c(c(c(c(c1I)NC(=O)C)I)C(=O)O)I
  • AHFS Code: 37:08.0
  • InChl: 1S/C11H9I3N2O4/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18/h1-2H3,(H,15,17)(H,16,18)(H,19,20)
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements